Listed

Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 8, 2019 and accepted by EDGAR at Nov 7, 2019, 18:29 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$26.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2019-01-01 to 2019-09-30$84.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2019-07-01 to 2019-09-30$12.5mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2019-01-01 to 2019-09-30$38.4mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-07-01 to 2019-09-30$14.0mus-gaap:GrossProfit
Gross profit9 months2019-01-01 to 2019-09-30$46.4mus-gaap:GrossProfit
Research and development3 months2019-07-01 to 2019-09-30$7.1mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$23.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-07-01 to 2019-09-30$20.7mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2019-01-01 to 2019-09-30$65.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-07-01 to 2019-09-30−$13.8mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30−$42.7mus-gaap:OperatingIncomeLoss
Interest expense3 months2019-07-01 to 2019-09-30$444.0kus-gaap:InterestExpense
Interest expense9 months2019-01-01 to 2019-09-30$3.6mus-gaap:InterestExpense
Income tax3 months2019-07-01 to 2019-09-30−$1.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2019-01-01 to 2019-09-30−$2.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30−$12.9mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30−$52.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30−$0.19us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30−$0.79us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2019-01-01 to 2019-09-30−$29.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$2.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-09-30$25.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$96.6mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$269.4mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$33.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$106.8mus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30$162.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001162194-19-000088. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.